HIV-1 envelope glycoprotein broadly neutralizing antibody epitope (Env bnAb epitope)

The HIV-1 envelope glycoprotein (Env) broadly neutralizing antibody epitope refers to specific regions on the surface of the viral spike protein formed by the trimeric gp120 and gp41 subunits that are recognized by a subset of antibodies capable of neutralizing diverse HIV-1 strains[1][3][4][6]. Env mediates viral attachment to host CD4 and co-receptors (CCR5/CXCR4), followed by conformational changes leading to membrane fusion[1][4][5][6]. These epitopes include conserved sites such as the CD4 binding site, V2/V3 loops, the fusion peptide, and the membrane-proximal external region (MPER) of gp41[3][6][2]. Broadly neutralizing antibodies (bnAbs) bind to these epitopes with high affinity and block infection by disabling critical steps in the entry process[3][4][6]. Env epitopes are the focus of vaccine and therapeutic antibody development, but their variability and protective glycan shield remain significant obstacles to eliciting effective immune responses[1][6]. Some drugs and antibodies (e.g., Enfuvirtide, VRC01) target these epitopes to prevent viral entry and fusion[3][5][6]. The ability to monitor patient antibody responses to Env bnAb epitopes serves as a biomarker for HIV-1 exposure and immune control[6].

Other names

HIV-1 Env broadly neutralizing antibody epitopeHIV-1 envelope neutralizing epitopeHIV Env bnAb epitopeEnvelope glycoprotein antibody epitope

Inhibition of virus-cell membrane fusion by blocking conformational changes in Env (gp120/gp41); Direct neutralization by binding the epitope and preventing receptor (CD4/co-receptor) engagement or fusion; Some antibodies lock Env in a closed conformation to prevent exposure of fusion elements